Stock Traders Purchase Large Volume of Cardlytics Call Options (NASDAQ:CDLX)

Cardlytics, Inc. (NASDAQ:CDLX) was the recipient of some unusual options trading activity on Thursday. Investors bought 8,115 call options on the stock. This is an increase of 375% compared to the average daily volume of 1,710 call options.

Cardlytics Stock Performance

Shares of NASDAQ CDLX opened at $9.27 on Friday. The company has a market capitalization of $446.57 million, a PE ratio of -2.68 and a beta of 1.50. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.31 and a current ratio of 1.31. The company’s fifty day moving average price is $12.53 and its 200 day moving average price is $9.73. Cardlytics has a 1 year low of $4.94 and a 1 year high of $20.52.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.14) earnings per share for the quarter. Cardlytics had a negative return on equity of 25.38% and a negative net margin of 43.56%. The firm had revenue of $89.17 million during the quarter.

Insider Activity at Cardlytics

In other news, COO Amit Gupta sold 23,416 shares of Cardlytics stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $11.91, for a total transaction of $278,884.56. Following the completion of the sale, the chief operating officer now directly owns 122,676 shares in the company, valued at $1,461,071.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, COO Amit Gupta sold 23,416 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $11.91, for a total value of $278,884.56. Following the completion of the transaction, the chief operating officer now directly owns 122,676 shares in the company, valued at $1,461,071.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Clifford Sosin bought 311,715 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was purchased at an average price of $13.71 per share, for a total transaction of $4,273,612.65. Following the transaction, the insider now owns 5,673,676 shares of the company’s stock, valued at $77,786,097.96. The disclosure for this purchase can be found here. Insiders sold 36,306 shares of company stock valued at $455,203 in the last three months. 4.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Cardlytics

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Cardlytics by 13.0% during the third quarter. Vanguard Group Inc. now owns 2,011,705 shares of the company’s stock worth $33,193,000 after purchasing an additional 231,303 shares in the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Cardlytics during the third quarter valued at about $5,258,000. Invesco Ltd. increased its position in shares of Cardlytics by 538.1% during the third quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock valued at $13,253,000 after acquiring an additional 677,354 shares during the last quarter. LPL Financial LLC raised its stake in shares of Cardlytics by 27.5% in the 3rd quarter. LPL Financial LLC now owns 424,150 shares of the company’s stock valued at $6,998,000 after acquiring an additional 91,400 shares during the period. Finally, New York State Common Retirement Fund lifted its holdings in shares of Cardlytics by 600.8% in the 3rd quarter. New York State Common Retirement Fund now owns 13,498 shares of the company’s stock worth $223,000 after acquiring an additional 11,572 shares during the last quarter. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Wall Street Analyst Weigh In

CDLX has been the subject of several recent research reports. Craig Hallum decreased their target price on shares of Cardlytics from $18.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday. Lake Street Capital lifted their price objective on Cardlytics from $13.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, Needham & Company LLC lowered their target price on Cardlytics from $17.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.